Linagliptin
Linagliptin
Definition
A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested.
Also known as (R)-8-(3-Amino-Piperidin-1-yl)-7-but-2-ynyl-3-Methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, 1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-, 8-((3R)-3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-3,7-Dihydro-1H-Purine-2,6-Dione, BI 1356 BS, BI-1356, LINAGLIPTIN, Tradjenta — per NCIT
Also identified as
- ATC A10BH05 per RXNORM
- NCIT NCIT:C83887 per NCIT
- SCTID 702798009 per RXNORM
- SCTID 703667006 per RXNORM
- UNII 3X29ZEJ4R2 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Diabetes mellitus type 2 | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Alimentary part of gastrointestinal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Pancreas | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.